Education
About Us
Working with TipRanks
Follow Us
MedAdvisor Limited (AU:AHE)
ASX:AHE
AHE Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.18
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.73M
Market Cap
AU$12.10M
Enterprise ValueAU$15.63M
Total Cash (Recent Filing)AU$10.30M
Total Debt (Recent Filing)AU$17.40M
Price to Earnings (P/E)―
Beta2.32
Next Earnings
Feb 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding636,978,100
10 Day Avg. Volume474,818
30 Day Avg. Volume1,728,714
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)11.59
Price to Sales (P/S)0.19
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$110.67M
Bulls Say, Bears Say
Bulls Say
Platform & Pharmacy NetworkMedAdvisor operates a platform that links pharmacies, pharma brands and consumers, offering medication management and adherence tools. That network creates durable, sticky relationships with pharmacies and brands, supporting recurring service revenue and long-term program deployment potential.
Revenue Model DiversificationThe company earns from both pharmacy software/services and life-sciences brand programs. This multi-channel model aligns incentives across pharmacies and pharma sponsors, reducing single-market dependence and enabling scaling of brand-funded programs as the network grows over months.
Improving Free Cash Flow GrowthReported positive free cash flow growth suggests improving cash conversion and potential progress on cost control or working-capital management. If sustained, rising FCF can extend runway, fund product development or support customer retention despite current operating losses.
Bears Say
Sharp Revenue DeclineA near-40% revenue drop materially reduces scale, undermines unit economics and weakens the value proposition to brand partners and pharmacies. Sustained top-line shrinkage constrains margin recovery, product investment and the ability to execute multi-month growth plans.
Deep Operating Losses And Weak MarginsSeverely negative margins indicate operations are burning cash and are not self-sustaining. Persistent losses curtail reinvestment, force external financing or dilution, and make achieving durable profitability over a 2-6 month horizon difficult without material cost or revenue turnaround.
Negative Equity And Solvency RiskNegative shareholders' equity and the unusual debt-to-equity metric point to balance-sheet stress and elevated refinancing risk. This structural weakness can limit strategic flexibility, increase counterparty concern and hinder long-term partnerships or investment unless remediated.
MedAdvisor Limited News
AHE FAQ
What was MedAdvisor Limited’s price range in the past 12 months?
MedAdvisor Limited lowest share price was AU$0.02 and its highest was AU$0.17 in the past 12 months.
What is MedAdvisor Limited’s market cap?
MedAdvisor Limited’s market cap is AU$12.10M.
When is MedAdvisor Limited’s upcoming earnings report date?
MedAdvisor Limited’s upcoming earnings report date is Feb 26, 2026 which is today.
How were MedAdvisor Limited’s earnings last quarter?
MedAdvisor Limited released its earnings results on Aug 28, 2025. The company reported -AU$0.109 earnings per share for the quarter, missing the consensus estimate of -AU$0.031 by -AU$0.078.
Is MedAdvisor Limited overvalued?
According to Wall Street analysts MedAdvisor Limited’s price is currently Undervalued.
Does MedAdvisor Limited pay dividends?
MedAdvisor Limited does not currently pay dividends.
What is MedAdvisor Limited’s EPS estimate?
MedAdvisor Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MedAdvisor Limited have?
MedAdvisor Limited has 636,978,100 shares outstanding.
What happened to MedAdvisor Limited’s price movement after its last earnings report?
MedAdvisor Limited reported an EPS of -AU$0.109 in its last earnings report, missing expectations of -AU$0.031. Following the earnings report the stock price went down -7.143%.
Which hedge fund is a major shareholder of MedAdvisor Limited?
Currently, no hedge funds are holding shares in AU:AHE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MedAdvisor Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.95%
12-Months-Change
Fundamentals
Return on Equity
-240.60%
Trailing 12-Months
Asset Growth
-59.67%
Trailing 12-Months
Company Description
MedAdvisor Limited
Adheris Health Limited, together with its subsidiaries, provides pharmacy-driven patient engagement solutions in Australia, the United States, and the United Kingdom. The company offers THRiV, an omni-channel platform which provides pharmacy-driven patient and pharmacist engagement solutions to improve medication management. The company was formerly known as MedAdvisor Limited and changed its anme to Adheris Health Limited in November 2025. The company was incorporated in 2010 and is based in Woburn, Massachusetts.